Skip to main content

Category: Other News Items

FDA Approves First Use of Tracer-QC at Gordon Center

Radiopharmaceutical company Trace-Ability, Inc. announced that the FDA has approved the first use of its solution, Tracer-QC, for release testing Ammonia N-13 Injection at the MGH Gordon Center PET Core. Tracer-QC automates the positron emission tomography (PET) tracer release testing process, which the company says is known for its complexity. “Despite the clear value of […]

Research Agreement Signed with Cerveau Technologies

Cerveau Technologies Inc. signed an agreement with the MGH Gordon Center to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.

2018 Human Amyloid Imaging Conference

The 12th Human Amyloid Imaging Conference will take place in Miami, Florida on January 17-19, 2018.
Dr. Keith Johnson is organizing the event with the help of co-organizers Dr. Bill Klunk (University of Pittsburgh), Dr. Chet Mathis (University of Pittsburgh) and Dr. Bill Jagust (University of California, Berkeley).
The conference includes podium and poster presentations on cutting edge research into biomarkers for Alzheimer’s-related disease.

PET Production Facility

The production facility is a cGMP/FDA registered PET drug manufacturer that consists of an ISO Class 8 manufacturing area, an ISO Class 7 cleanroom and a quality control lab. The core laboratories are equipped with over 20 mini cells and automated chemistry modules used primarily for the synthesis of 18F, 11C and 13N radiopharmaceuticals. Click […]

Next Page » « Previous Page